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OBJECTIVES: Emergency room (ER) visits are perceived with the high costs and 
unpredictable outcomes. Although the association between Attention Deficit 
Hyperactivity Disorder (ADHD), stimulants and ER visits has been studied; differ-
ence between the types of stimulants in terms of risk of ER visits have not been 
studied. Our objective is to identify the difference between the effects of long act-
ing and short acting stimulant use in ADHD on ER visits in 18 to 35 year old adults 
(n= 636) in the year 2011. METHODS: This retrospective secondary data analysis 
used the Medical Expenditure Panel Survey (MEPS) data for the year 2011. Univariate 
and Multivariate logistic regression were used to evaluate risk factors influencing 
type of stimulant use on ER visits. Risk factor and stimulant interactions were also 
included. RESULTS: The risk of ER visits in long acting stimulant users, among 
the uninsured, on adjusting for race, marital and insurance status, is 14.25 times 
(p= 0.001) the risk of ER visits in short acting stimulant users. If they are insured, 
the risk of ER visits in long acting stimulant users is 1.83 times the risk of ER visits 
in short acting stimulant users (p= 0.26). CONCLUSIONS: Long-acting stimulants 
combined with lack of insurance is a risk factor for increased ER visits. Our results 
support Affordable Care Act’s efforts for the requirements of expansion on coverage 
in mental disorders to reach better healthcare outcome.
MentAl HeAltH – cost studies
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ReAl-WoRld Budget iMPAct AnAlysis of AtyPicAl long-Acting Anti-
PsycHotics in finlAnd
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OBJECTIVES: The long-acting injectable aripiprazole once-monthly 400 mg (AOM 
400) has been approved for treatment of schizophrenia in Finland since November 
2013. Other atypical anti-psychotics, risperidone, paliperidone and olanzapine are 
also available as long-acting injectable formulations. A mixed treatment comparison 
has demonstrated that AOM 400 is at least as efficacious as other atypical long-
acting anti-psychotics (ALAIs). However, cost of administration and drug (treatment 
cost) vary among the ALAIs. This analysis aims to investigate the total treatment 
costs of ALAIs using real-world data in Finland. METHODS: A one-year time horizon 
budget impact analysis was conducted to compare the treatment costs of ALAIs in 
Finland. The real-world doses were calculated using sales data. One of the ALAIs 
(olanzapine) can be given in intervals of 2 or 4 weeks using the 300 mg strength. Half 
of the patients were assumed treated with the 300 mg dose every 2 weeks, the other 
half every 4 weeks. Prices for ALAIs were obtained from the official national price 
list. The cost of administration for AOM 400, paliperidone-LAI and risperidone-LAI 
was based on the cost of a short nurse visit (30 minutes) to a psychiatry outpatient 
clinic. The cost of administration of olanzapine-LAI was based on the cost of a longer 
visit (120-180 minutes), as the product information recommends monitoring for 
three hours after injection. RESULTS: The expected cost for drug and administration 
per patient, per year, for AOM 400 is 5158 EUR. The expected yearly costs per patient 
for drug and administration for paliperidone-LAI, risperidone-LAI and olanzapine-
LAI are 6021 EUR, 6706 EUR and 11646 EUR respectively. CONCLUSIONS: In a budget 
impact analysis, using the method, data and assumptions described, AOM 400 is 
expected to be cost saving, in the real-world setting, in terms of cost of drug and 
administration, compared to other ALAIs available in Finland.
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OBJECTIVES: To compare healthcare utilization and costs between early- and 
late-stage Alzheimer’s disease (AD) patients residing in long-term care (LTC) 
facilities. METHODS: Patients diagnosed with AD (International Classification of 
Diseases, 9th Revision, Clinical Modification [ICD-9-CM] code 331.0) were identified 
using U.S. Medicare claims linked with the Long-Term Care Minimum Data Set (MDS) 
from 01JULY2008 through 31DEC2010. The first diagnosis date was designated as 
the index date. Patients were required to be age ≥ 65 years, with continuous medical 
and pharmacy benefits for 6 months pre- and post-index date, and reside in an LTC 
facility. Patients were categorized as early- or late-stage. Late-stage AD was defined 
by a cognitive performance scale score ≥ 5 (range 0-6) and Activities of Daily Living 
short-form activities score ≥ 10 points. Patients with and without AD were matched 
based on demographic and clinical characteristics, and 1:1 propensity score match-
ing was used to compare follow-up all-cause and AD-related healthcare costs and 
utilizations. RESULTS: Before matching, late-stage AD patients (n= 5,323) were less 
likely to be white (83.0% vs. 86.4%), male (16.4% vs. 21.7%) and have comorbid condi-
tions measured by the Charlson Comorbidity Index score (3.55 vs. 4.83, p< 0.001) than 
early-stage AD patients (n= 20,023). After 1:1 matching, 3,804 patients were matched 
from each cohort and baseline characteristics were balanced. Fewer late-stage AD 
patients had skilled nursing facility admissions (25.3% vs. 29.8%, p< 0.0001), but more 
had hospice admissions (17.8% vs. 7.3%, p< 0.0001) and pharmacy visits (85.8% vs. 
81.9%, p< 0.0001) than early-stage AD patients. There were no significant differences 
in total all-cause healthcare costs; however, late-stage AD patients incurred signifi-
cantly higher disease-related total ($14,739 vs. $13,673, p= 0.0242) and hospice costs 
($4,157 vs. $1,553, p< 0.0001) compared to early-stage AD patients. CONCLUSIONS: 
Patients with late-stage AD incurred higher disease-related costs than those with 
early-stage AD; however, there were no significant differences in total all-cause 
healthcare costs.
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OBJECTIVES: Pharmacy databases can yield important information about drug uti-
lization and costs. This study sought to examine changes in prescription utilization 
and costs among atypical antipsychotic (AAP) subjects initiating lurasidone or ari-
piprazole therapy. METHODS: Adults filling lurasidone or aripiprazole prescriptions 
from 2/3/2011—6/30/2013 were identified in the Walgreens pharmacy-database. 
Treatment-naive monotherapy subjects (no AAP prescriptions before-and-after 
index prescription) with ≥ 12-months pre-/post-index continuous enrollment 
were eligible. Lurasidone subjects were compared to a 1:1 matched random sam-
ple of aripiprazole subjects. Baseline demographics and health-insurance status 
were compared between cohorts. Mental-health prescriptions (antianxiety agents, 
antidepressants, antipsychotics, psychotherapeutic, and neurologic agents) were 
identified using Generic Product Identifier for the National Drug Code numbers on 
pharmacy claims. Differences in mean changes (post-pre) in all-cause prescrip-
tion fills all-cause prescription costs, mental-health prescription fills and mental-
health costs were compared using t-tests. RESULTS: Each cohort included 4,595 
subjects (lurasidone vs aripiprazole: 69.3% vs 72.2% female, mean ages 41.0 vs 43.4 
years). Most subjects were commercially-insured (39.9% vs 48.6%), followed by State-
Medicaid (24.4% vs 18.7%), Medicare-Part-D (22.8% vs 18.7%), and Managed-Medicaid 
(6.8% vs 5.6%). Lurasidone subjects had lower 30-day equivalent co-pays ($42.02 vs 
$56.63). Subjects were more likely to be prescribed lurasidone by psychiatrists (78.0% 
vs 57.3%) and less likely by general-practitioners (3.1% vs 23.0%). Overall, lower 
mean increases in all-cause prescription fills (11.3 vs 12.3;p= .09) and mental-health 
prescription fills (7.2 vs 8.0;p< .01) were observed for lurasidone than aripiprazole 
subjects. Additionally, mean differences in all-cause prescription costs ($2,388 vs 
$3,080;p< .01) and mental-health prescription costs ($2,123 vs $2,810;p< .01) were 
lower for lurasidone than aripiprazole subjects. Similar patterns of mean changes in 
prescription utilization and costs were found in commercial, Medicaid and Medicare 
subjects. CONCLUSIONS: In this national-US pharmacy-database analysis compar-
ing subjects initiating branded AAPs, lurasidone subjects had fewer mean changes in 
all-cause and mental-health prescriptions and lower mean increases in associated 
costs than aripiprazole subjects.
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OBJECTIVES: Dementia is associated with high costs of national healthcare in 
European countries. Disruptive neuropsychiatric symptom (NPS) such as agitation 
and aggression (A/A), increase caregiver burden, lead to premature institutionaliza-
tion and death, and increase dementia costs. The aim of this study is to estimate 
the incremental societal costs for Patients with Dementia (PwD) with A/A in both 
Community-Dwelling (CD) and long-term care (LTC) settings in 8 European coun-
tries. METHODS: This study uses data fromthe RightTimePlaceCare (RTPC) European 
project. Interviews using structured questionnaires are conducted with 2014 PwD 
and their primary informal caregivers. Direct and informal costs are estimated from 
a societal perspective. Resource utilization is assessed with the resource utilization 
in dementia instrument. Resource consumption is valued using unit costs for each 
country, the replacement cost approach (informal care) and retail prices (medica-
tion).To estimate incremental costs of A/A, costs for PwD with A/A are compared 
to costs for PwD without A/A in both settings. Special emphasis is placed on the 
main predictors of costs. RESULTS: 2002 patients completed agitation item into 
the NeuroPsychiatric Inventory-Questionnaire at baseline (i.e. 1219 CD and 883 
LTC). For CD patients with A/A societal costs are 2,472€ for one month vs. 2,144€ 
for patient without A/A (p= 0.002). Incremental costs of A/A for CD patients are 
mainly due to informal costs and inpatient costs which are+174€ (p= 0.015) and 
+113€ (p= 0.048), respectively. For LTC patients with A/A societal costs are 4,730€ for 
one month vs. 4,166€ for patients without A/A (p= 0.003). Incremental costs of A/A 
for LTC patients are mainly due to nursing home costs and outpatient costs which 
are +353€ (p= 0.003) and +148€ (p= 0.000), respectively. CONCLUSIONS: A/A in PwD 
living at home or in LTC setting increase societal costs by 15%.
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OBJECTIVES: Schizoaffective disorder, with both mood and psychotic symptoms, 
may necessitate different treatment than other schizophrenia subtypes. Long-
acting injectable antipsychotics may reduce hospitalizations among schizophrenia 
patients but generalizability to schizoaffective disorder is unclear. This study com-
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pared all-cause utilization and costs associated with once-monthly paliperidone 
palmitate (PP) and oral atypical antipsychotics (OAT) in Medicaid and commercially-
insured schizoaffective disorder populations. METHODS: Adults with schizoaffec-
tive disorder and ≥ 2 claims for PP or OAT between 2009-2012 were identified in the 
MarketScan Medicaid and Commercial Databases, and followed 6 months before and 
12 months after initiating PP or OAT. Weighting and marginal structural modeling 
controlled for cohort differences and time-varying confounding to estimate patient-
month utilization and costs. RESULTS: Medicaid PP patients (n= 1320) were more 
likely male (53% vs. 42%, p< 0.05) and younger (mean age 38 vs. 40 years, p< 0.05) than 
OAT patients (n= 4216). Pre-index mood stabilizer use appeared similar for PP and 
OAT patients (55% vs. 53%, p= 0.42), but antidepressants were less common among PP 
patients (60 vs. 69%, p< 0.05). Risk of all-cause and mental health hospitalization and 
emergency department utilization was reduced (25.1%, 27.8%, 11.1% respectively, 
all p< 0.05) in patient-months with PP administration. Lower mean inpatient ($-185, 
95% confidence interval [CI] $-40-$-331) and outpatient ($-229, 95% CI $-69-$-389) 
costs in these months partially offset higher mean drug costs ($1136, 95% CI $1063-
$1209), reducing the modeled monthly cost differential associated with PP vs. OAT 
to $722 (95% CI $526-$917). Patient characteristics and utilization and cost trends 
for commercial PP (n= 167) and OAT (n= 2044) populations were similar to those 
observed in the Medicaid sample, although cost offsets did not reach statistical 
significance. CONCLUSIONS: Drug costs were higher in patient-months with PP 
administration; however, compared to patient-months without PP administration, 
there was a 25.1% reduction in all-cause hospitalization risk and a 24.1% reduction 
in inpatient costs.
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Hagiwara M.1, Sun S.X.2, Moynahan A.1, Bornheimer R.1, Oster G.3
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2Forest Research Institute, Jersey City, NJ, USA, 
3Policy Analysis Inc. (PAI) and Managing Co-Director, MINERVA Health Economics Network, 
Brookline, MA, USA
OBJECTIVES: While antidepressant medications constitute the mainstay of phar-
macologic management of MDD, patients with poor response are sometimes 
treated adjunctively with SGAs, such as aripiprazole, quetiapine, and olanzapine. 
This study estimated healthcare utilization and costs among patients with MDD 
initiating adjunctive therapy with SGAs, using a large US healthcare claims data-
base. METHODS: Adult patients receiving oral SGAs between 2009 and 2011 without 
evidence of schizophrenia or bipolar disorder were identified in the Truven MedStat 
MarketScan® Commercial Claims and Encounters and Medicare Supplemental and 
Coordination of Benefits Database. The “index date” was defined as the date of 
first receipt of an SGA. Patients with enrollment gaps during the 12-month period 
before the index date (pre-index period) or after the index date (follow-up period), 
no diagnosis of MDD during the pre-index period, no evidence of antidepressant 
medications overlapping their index date, or evidence of SGA prescriptions during 
the pre-index period were excluded. Healthcare utilization and costs were examined 
over the pre-index and follow-up periods. Healthcare encounters with diagnoses 
of MDD (ICD-9-CM 296.2, 296.3), and SGA and antidepressant prescriptions were 
designated “MDD-related”. RESULTS: A total of 17,697 patients met study criteria. 
The most frequently prescribed SGA was aripiprazole (56.3%), followed by quetia-
pine (34.3%), risperidone (13.4%), and olanzapine (7.8%). During the pre-index and 
follow-up periods, 27% and 7.5% of patients, respectively, were hospitalized for 
MDD (p< .0001), 37% and 20% were hospitalized for any reason (p< .0001), and 37% 
and 31% had ≥ 1 emergency department (ED) visits (p< .0001). Mean MDD-related 
total health care costs during the pre-index and follow-up periods were $5427 vs 
$6222, respectively (p< 0.0001). The average cost of SGAs during follow-up was 
$2154. CONCLUSIONS: Initiation of adjunctive therapy with SGAs in MDD patients 
is associated with a lower incidence of hospitalization (MDD-related and all-cause) 
and ED visits.
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OBJECTIVES: To evaluate healthcare resource utilization and costs among schizo-
phrenic patients who initiated typical and atypical long-acting injectables (LAIs) in 
the U.S. veteran population. METHODS: Using the Veterans Health Administration 
(VHA) Medical SAS datasets, patients with ≥ 1 pharmacy claim for LAIs were iden-
tified from 01OCT2005 through 30SEPT2012. The first LAI date was designated as 
the index date. Patients were required to be age ≥ 18 years, have continuous health 
plan enrollment for 12 months pre-index date and a schizophrenia diagnosis 
(International Classification of Diseases, 9th Revision, Clinical Modification [ICD-
9-CM] code 295.xx) during the study period. Patient data was observed until the 
earlier date of death or the end of the study period, and patients were assigned to 
typical LAI (fluphenazine, haloperidol, perphenazine) or atypical LAI (aripiprazole, 
olanzapine, paliperidone, risperidone) antipsychotic cohorts. All-cause (follow-up) 
and psychiatric disorder-related healthcare resource utilization and costs were 
assessed. Follow-up health care costs were adjusted to per-patient-per-month. 
The generalized linear model (GLM) was used to assess cost and utilization dif-
ferences among the cohorts. RESULTS: A total of 4,796 patients were identified 
(Typical LAI cohort: N= 1,941; Atypical LAI cohort: N= 2,855). Typical LAI patients 
were older (age 53.81 vs. 50.94 years, p< 0.0001) and more likely to be black (34.47% 
vs. 28.27%, p< 0.0001) than atypical LAI patients. After adjusting for baseline differ-
ences using GLM, more patients prescribed typical LAIs had all-cause emergency 
room [ER] visits (61.66% vs. 58.11%, p= 0.024) and inpatient stays (63.11% vs. 59.00%, 
p= 0.008) and psychiatric disorder-related ER visits (33.83% vs. 30.05%, p= 0.011) 
than those prescribed atypical LAIs. However, typical LAI patients incurred lower 
all-cause pharmacy ($197 vs. $433, p< 0.001), total ($2,850 vs. $3,073, p= 0.048) and 
psychiatric disorder-related total costs ($1,615 vs. $1,624, p= 0.908) than atypical LAI 
patients. CONCLUSIONS: Although patients who initiated typical LAIs had high 
healthcare resource utilization, their economic burden was lower compared to those 
who initiated atypical LAIs.
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OBJECTIVES: Clinical trial PSY-3012 was a randomized, multicenter, double-blind, 
parallel-group, relapse-prevention study of paliperidone palmitate 3-month injec-
tion (PP3M) versus placebo. Adults with schizophrenia received a once-monthly 
injection (PP1M) in an open-label (OL) 17-week transition phase, then a single PP3M 
injection for OL 12-week maintenance. Stabilized subjects were then randomized 
to PP3M or placebo in the double-blind (DB) phase. Exploratory objectives were 
to compare health resource utilization (HRU) and costs between PP3M and pla-
cebo. METHODS: HRU data were collected at the start of transition (OL baseline) 
and maintenance, at the end of open-label (DB baseline), and every 12 weeks 
during DB until end of study/early withdrawal. Information collected included 
hospitalizations, ER visits, day or night clinic stays, and outpatient treatment. 
Incidence rates (i.e., person-time) at OL baseline and during OL and DB phases 
were calculated for these resources. RESULTS: Overall, 145 subjects were ran-
domized to placebo and 160 subjects to PP3M during the DB phase. During the 
DB phase, incidence rate was < 1 event per person-year for all resources except 
outpatient treatment visits in both treatment groups and was higher for placebo 
than for PP3M. Hospitalizations with psychiatric and social reasons: incidence 
rate at baseline OL was similar between placebo and PP3M (0.51 vs. 0.58 hos-
pitalizations per person-year), decreased to comparable values during the OL 
phase (0.12 vs. 0.14 hospitalizations per person-year), and increased during the 
DB phase to 0.45 (placebo) and 0.15 (PP3M). Other HRU resources showed analo-
gous trends. CONCLUSIONS: During the DB phase, the incidence rate of HRU was 
numerically lower for PP3M than placebo. The incidence rate of most HRU was 
comparable between placebo and PP3M during the OL period, but increased more 
for placebo than for PP3M during the DB period. Ongoing analysis of the cost data 
will provide further insight into the economic impact of PP3M.
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OBJECTIVES: To assess the impact of anxiety and of the depression-anxiety 
interaction on healthcare utilization and costs among patients with depres-
sion. METHODS: Survey-eligible adults with ≥ 2 medical claims for depression 
from 6/1/2009-5/31/2010 in the HealthCore Integrated Research Database were 
invited to participate in this retrospective/prospective study. Consenting respond-
ents completed index and 6-month surveys assessing health measures. Significant 
anxiety was classified into 4 categories (persistently anxiety free, persistent 
anxiety, resolving anxiety, and emerging anxiety) based on Generalized Anxiety 
Disorder (GAD-7) scores at both surveys. Respondents’ survey data were linked 
to 24-months of claims data (+12 months from index survey date). Mean annual 
post-index costs were compared using non-parametric bootstrapping adjusting 
for initial differences in demographics and health status using propensity score 
stratification. Similar models were created adding the interaction of remission 
status. RESULTS: Of 910 respondents with both surveys, 79.3% were female and 
mean (SD) age was 47.6 (11.4) years. Most respondents were persistently anxi-
ety free (52.9%), followed by persistent anxiety (23.4%), resolving anxiety (15.1%), 
and emerging anxiety (8.7%). Higher post-index all-cause healthcare costs were 
observed in respondents with persistent anxiety compared to others (combined 
group of resolving, emerging, or persistently anxiety-free) ($15,027 [$1,838] vs. 
$11,311 [$680], p= .0018). Persistent anxiety respondents had significantly higher 
mental health-related costs than persistently anxiety free respondents ($4,226 
[$551] vs. $3,044 [$332], p< .001). Respondents with anxiety and non-remitted 
depression had significantly higher all-cause and mental-health related costs 
vs. respondents without anxiety and non-remitted depression, with mean differ-
ences of $2,480 (95% CI: $337 to $4,685, p< .0001) and $789 (95% CI: $146 to $1,428, 
p< .0001), respectively. CONCLUSIONS: Respondents with a history of depression 
and persistent anxiety continue to have increased healthcare costs. Anxiety was 
a key factor irrespective of whether depression resolved. This study emphasizes 
the importance of treating patients to full resolution of all symptoms.
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OBJECTIVES: To examine differences in healthcare resource use (HRU) and cost 
among patients with schizophrenia initiating therapy with asenapine versus other 
branded atypical antipsychotics (“OBAP”) (i.e., aripiprazole, lurasidone, iloperidone, 
paliperodone). METHODS: Using two large US healthcare claims databases—one 
